Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer

Exclusion Criteria

• •1. Allergic disease history, severe hypersensitivity to drugs, antibody products or Sintilimab;
• •2. Other malignancy history with disease free survival \<5 years, except for curative in situ cervical cancer, curative skin basal cell carcinoma and curative gastrointestinal cancer by endoscopic mucoresection;
• •3. Current or past history of autoimmune diseases, including but not limited to: interstitial lung disease, uveitis, enteritis，active hepatitis (HBV DNA≥103 copies/mL after regular antiviral therapy)，nephritis, hyperthyroidism and hypothyroidism;
• •4. Immunosuppressant or corticosteroid (systemic or local) use to suppress immune function within 2 weeks before inclusion;
• •5. Severe infection needing intravenous antibiotics, antifungal agents or antiviral drugs, et al;
• •6. Congenital or acquired immunodeficiency such as HIV infection; active Hepatitis B (HBV DNA≥103 copies/mL after regular antiviral therapy);
• •7. Having one of the following complications: massive gastrointestinal hemorrhage, gastrointestinal perforation or obstruction; symptomatic heart diseases including unstable angina, myocardial infarction and heart failure; uncontrollable diabetes mellitus or hypertension; uncontrollable diarrhea (interfering with daily activities although receiving adequate treatment);
• •8. Bleeding tendency or receiving thrombolytic or anticoagulant therapy;
• •9. Pregnant or breastfeeding female; male and female unwilling to take any contraceptive measures;
• •10. Psychiatric disorders that would interfere with cooperation with the requirements of the study;
• •11. Other conditions that investigators consider not suitable for this study.